一種針對(duì)肺、卵巢、乳房癌癥進(jìn)行早期檢測(cè)和危險(xiǎn)分層的新方法，將由創(chuàng)建新型蛋白質(zhì)組學(xué)技術(shù)來(lái)完稱(chēng)，其原理是精確地檢測(cè)和測(cè)定特異性的蛋白質(zhì)片斷，這些片斷是人血液中可能的疾病生物學(xué)指標(biāo)。

PerkinElmer公司(Boston, MA, USA)已經(jīng)宣布了一項(xiàng)為期5年與George Mason大學(xué)(Manassas, VA, USA)合作的科研計(jì)劃，以實(shí)現(xiàn)這種新型檢測(cè)方法。PerkinElmer公司提供基因生物指標(biāo)領(lǐng)域新技術(shù)和科學(xué)方法。來(lái)自這兩個(gè)機(jī)構(gòu)的科學(xué)家將共同合作設(shè)計(jì)新型臨床檢測(cè)平臺(tái)，該平臺(tái)將同時(shí)對(duì)特異性蛋白質(zhì)片斷的進(jìn)行氨基酸鑒別和特定分子量進(jìn)行鑒別，以發(fā)現(xiàn)生物指標(biāo)。
 
Proteomics Technology May Detect Early Cancer
 
A new approach for early lung, ovarian, and breast cancer detection and risk stratification is being developed by creating a new proteomics technology to accurately detect and measure specific protein fragments in human blood that are potential biomarkers for disease.

PerkinElmer, Inc. (Boston, MA, USA), has announced a five-year research-collaboration agreement with George Mason University (Manassas, VA, USA) to work on this new approach. PerkinElmer is providing new technology and scientific expertise in genetic biomarker expression. Scientists from both organizations will work together to design new types of clinical assay latforms that use both the amino acid identification of a specific protein fragment and its specific mass to identify the biomarker.